Takeda Announces Ricardo Marek as New President of Emerging Markets Business Unit

3 Apr 2017
Mia Harley
Biochemist

Industry news

Takeda Pharmaceuticals Company Limited have announced that Ricardo Marek has been appointed as the President of the Emerging Markets Business Unit (EMBU), based in Singapore, effective April 1, 2017. In his new role he will lead allbusiness operations across five geographic Areas that compriseEM BU – Asia Pacific (excluding Japan), China, Latin America, Middle East & Africa and Russia-CIS. Marekwill also serve as a Corporate Officer and member of Takeda’s Executive Team, and report to Christophe Weber, President and Chief Executive Officer of Takeda.

After joining Takeda in 2011, Ricardo became President of Takeda Brazil in 2013. He then took-on additional, concurrent responsibilities, as Area Head of Latin America (LatAm) in 2014. Ricardo will be relocating from his home in São Paulo, Brazil, to Singapore and succeeds Giles Platford who has moved to Zurich as President of Europe and Canada, also effective April 1, 2017.

“The Emerging Markets is one of Takeda’s core growth drivers. Ricardo’s success in delivering solid growth in Latin America over the last six years, coupled with his strong leadership skills and commercial acumen makes him well placed to lead this business unit,” commented Christophe Weber, President & CEO of Takeda. “Ricardo has an impressive track-record spanning over 15 years in leadership positions. I am confident he will continue to lead our teams to great success in their work to deliver better health and a brighter future to patients.”

Marek’s experience also includes completing strategic acquisitions for Takeda across LatAm as well as launching the Oncology business in that part of the world for some of Takeda’s potentially life-saving and life-transforming medicines. His commitment to his employees and the development of talent has resulted in the countries under his remit being recognized with external awards from both the Great Place to Work® and Top Employer® Institutes. He holds an MBA from the University of São Paulo, Brazil.

Links

Tags

Biopharmaceutical AdvancesBiopharmaceutical advances follow the development of pharmaceuticals derived from biotechnology, also known as biotechnology medicines. Biopharmaceuticals may be produced from cell lines, plants, or microbial cells. Important considerations of biopharmaceutical use include application, cost, production process and purification.Shipping / PackagingPackaging is the technology of enclosing or protecting products for distribution, storage, sale, and use and the process and production of packages. Packaging is closely linked to Shipping and the preparing of goods for transport, warehousing, logistics, sale, and end use. Within the pharmaceutical industry packaging and shipping are used for transport, storage and logistics between Contract Research Organizations (CROs), Manufacturing and Clinical Trial companies. Packaging is also critical in the final production of a pharmaceutical product before market. RegulatoryPharmaceutical regulations impact on all areas of drug development, manufacture and control and supply. Services are provided from the early stages of drug development and clinical trials through to dossier submission, approval and marketing. Regulatory also includes submission of analytical studies from the pharmaceutical product and safety. BiopharmaceuticalsBiopharmaceuticals are proteins and other compounds (such as nucleic acids) produced by living organisms that have uses as therapeutics or for in vivo diagnostics. The most well known example of a biopharmaceutical product, and the first to be approved for therapeutic use, was recombinant human insulin.PharmaceuticalsPharmaceuticals are medicinal drugs used in healthcare to diagnose, prevent, cure and treat illnesses. Pharmaceuticals that are excreted after use appear in wastewater and can have detrimental effects on the environment.